欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (7): 754-761.doi: 10.12092/j.issn.1009-2501.2022.07.005

• 基础研究 • 上一篇    下一篇

西黄丸对H22荷瘤小鼠的抑瘤作用及其机制研究

刘艳之1,4,王艳2,3,刘凯丽2,3,周文华2,朱平4,王颖莉2,3,杜守颖1   

  1. 1北京中医药大学,北京 100085;2山西中医药大学,晋中 030619,山西;3山西省现代中药工程实验室,晋中 030619,山西;4山西振东安欣生物制药有限公司,晋中 030600,山西

  • 收稿日期:2022-03-15 修回日期:2022-06-15 出版日期:2022-07-26 发布日期:2022-08-11
  • 通讯作者: 王颖莉,女,博士,教授,从事中药化学及质量控制研究。 E-mail: wyl@sxtcm.edu.cn 杜守颖,女,博士,教授,从事中药制剂及研究。 E-mail: Dushouying@263.com
  • 作者简介:刘艳之,女,硕士,从事中药化学及质量控制研究。 E-mail: liuyz@zdjt.com
  • 基金资助:
    山西省教育厅项目(2021L362);西黄丸对肝癌的抑制作用研究(SXZY201807);西黄丸对肝癌的抑制作用深入研究(SXZY202201)

Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor

LIU Yanzhi 1,4, WANG Yan 2,3, LIU Kaili 2,3, ZHOU Wenhua 2, ZHU Ping 4, WANG Yingli 2,3, DU Shouying 1   

  1. 1 Beijing University of Chinese Medicine, Beijing 100102, China; 2 Shanxi University of Traditional Chinese Medicine, Jinzhong 030619, Shanxi, China; 3 Laboratory of Modern Chinese Medicine in Shanxi Province, Jinzhong 030619, Shanxi, China; 4 Shanxi Zhendong Anxin biopharmaceutical Co . , Ltd, Jinzhong 030600, Shanxi, China
  • Received:2022-03-15 Revised:2022-06-15 Online:2022-07-26 Published:2022-08-11

摘要: 目的:研究西黄丸对H22荷瘤小鼠的抑制作用及相关作用机制。方法:采用H22荷瘤小鼠模型分析西黄丸对肿瘤抑制作用;流式细胞仪测定血中CD3+、CD4+、CD8+细胞含量;酶联免疫法测定相关因子含量。网络药理学预测其抑制肝癌的相关通路,并用蛋白免疫印迹法(Western blot)对关键蛋白靶点验证。结果:西黄丸给药组可降低H22荷瘤小鼠的肿瘤重量(P<0.05);升高胸腺指数、脾脏指数(P<0.05),升高CD4+/CD8+水平(P<0.05);升高IL-2、IFN-γ的水平,降低IL-6、IL-10的水平(P<0.05)。网络药理学筛选得到77个重要有效成分,28个核心靶点,Western blot验证显示,西黄丸对PI3K-Akt-MMP9通路关键蛋白靶点有显著调节作用。 结论:西黄丸具有抑制肝癌移植瘤的作用,纠正患瘤小鼠的免疫紊乱,其作用机制与多成分多靶点的整合调节效应有关。

关键词: 西黄丸, H22肝癌细胞, 网络药理学, 整合调节

Abstract: AIM: To study the inhibitory effect of Xihuang Pill on H22 tumor-bearing mice and its related mechanism.  METHODS: The H22 tumor-bearing mouse model was used to analyze the inhibitory effect of Xihuang Pill on tumor; the contents of CD3+, CD4+, and CD8+ cells in blood were determined by flow cytometry; the contents of related factors were determined by enzyme-linked immunosorbent assay. Network pharmacology predicted the relevant pathways of its inhibition of liver cancer, and verified the key protein targets by Western Blot. RESULTS: Xihuang pill administration group could reduce the tumor weight of H22 tumor-bearing mice (P<0.05); increase the thymus index and spleen index (P<0.05), and increase the level of CD4+/CD8+ (P<0.05); The levels of IL-2 and IFN-γ decreased the levels of IL-6 and IL-10 (P<0.05). 77 important active ingredients and 28 core targets were obtained through network pharmacology screening. Western blot verification showed that Xihuang pills had a significant regulatory effect on the key protein targets of PI3K-Akt-MMP9 pathway. CONCLUSION: Xihuang pill has the effect of inhibiting the transplanted tumor of liver cancer and correcting the immune disorder of the tumor-bearing mice.

Key words: Xihuang pill, H22 liver cancer cell, network pharmacology, integrated regulation

中图分类号: